PeptidePedia The community reference

GLP-1 receptor agonist: difference between revisions

Diff·revision 12 → 13·00:26, 21 Oct 2024

Difference between revision 12 and revision 13 of GLP-1 receptor agonist. 2 lines changed; the page grew by 187 bytes.

Revision 12 — 18:54, 6 Oct 2024
EndpointEnid (talk)
correct the molar mass — source gives the free-base figure, we had the salt
6,120 bytes +584
Revision 13 — 00:26, 21 Oct 2024
LOD_Lorcan (talk)
expand §Molecular strategies for half-life extension
6,307 bytes +187
1{{Infobox concept1{{Infobox concept
2| name = GLP-1 receptor agonist2| name = GLP-1 receptor agonist
+3| subtitle = Drug class
3| image = receptor.svg4| image = receptor.svg
4| caption = Class B G-protein-coupled receptor engagement by an acylated peptide agonist.5| caption = Class B G-protein-coupled receptor engagement by an acylated peptide agonist.
12| Small molecule = [[Orforglipron]] (investigational)13| Small molecule = [[Orforglipron]] (investigational)
13}}14}}
+15{{hatnote|For the endogenous hormone, see [[Glucagon-like peptide-1]]. For agonists acting at more than one incretin receptor, see [[Dual incretin agonist]].}}
1416
15A '''GLP-1 receptor agonist''' ('''GLP-1 RA''') is a drug that activates the [[GLP-1 receptor]], reproducing and prolonging the actions of the endogenous incretin hormone [[Glucagon-like peptide-1]]. The class was developed for type 2 diabetes and has since been approved, for several of its members, for the treatment of obesity and for reduction of cardiovascular risk.{{r|drucker2018}}17A '''GLP-1 receptor agonist''' ('''GLP-1 RA''') is a drug that activates the [[GLP-1 receptor]], reproducing and prolonging the actions of the endogenous incretin hormone [[Glucagon-like peptide-1]]. The class was developed for type 2 diabetes and has since been approved, for several of its members, for the treatment of obesity and for reduction of cardiovascular risk.{{r|drucker2018}}